UroGen Pharma Ltd. UR8.F Stock
UroGen Pharma Ltd. Price Chart
UroGen Pharma Ltd. UR8.F Financial and Trading Overview
| UroGen Pharma Ltd. stock price | 15.5 EUR |
| Previous Close | 11.1 EUR |
| Open | 10.8 EUR |
| Bid | 10.8 EUR x 0 |
| Ask | 11.7 EUR x 0 |
| Day's Range | 10.8 - 10.8 EUR |
| 52 Week Range | 5.65 - 12.5 EUR |
| Volume | 200 EUR |
| Avg. Volume | 12 EUR |
| Market Cap | 253.3M EUR |
| Beta (5Y Monthly) | 0.754929 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.6 EUR |
UR8.F Valuation Measures
| Enterprise Value | 309.67M EUR |
| Trailing P/E | N/A |
| Forward P/E | -2.9427793 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.7258215 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 4.555 |
| Enterprise Value/EBITDA | -3.96 |
Trading Information
UroGen Pharma Ltd. Stock Price History
| Beta (5Y Monthly) | 0.754929 |
| 52-Week Change | 107.07% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 12.5 EUR |
| 52 Week Low | 5.65 EUR |
| 50-Day Moving Average | 9.46 EUR |
| 200-Day Moving Average | 8.74 EUR |
UR8.F Share Statistics
| Avg. Volume (3 month) | 12 EUR |
| Avg. Daily Volume (10-Days) | 20 EUR |
| Shares Outstanding | 23.45M |
| Float | 19.65M |
| Short Ratio | N/A |
| % Held by Insiders | 9.96% |
| % Held by Institutions | 69.60% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -164.15% |
| Operating Margin (ttm) | -116.39% |
| Gross Margin | 87.65% |
| EBITDA Margin | -115.030% |
Management Effectiveness
| Return on Assets (ttm) | -35.49% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 67.99M EUR |
| Revenue Per Share (ttm) | 2.96 EUR |
| Quarterly Revenue Growth (yoy) | 26.70% |
| Gross Profit (ttm) | 56.7M EUR |
| EBITDA | -78203000 EUR |
| Net Income Avi to Common (ttm) | -111604000 EUR |
| Diluted EPS (ttm) | -5.35 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 65.05M EUR |
| Total Cash Per Share (mrq) | 2.77 EUR |
| Total Debt (mrq) | 100.31M EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 3.803 |
| Book Value Per Share (mrq) | -4.972 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -89370000 EUR |
| Levered Free Cash Flow (ttm) | -43794500 EUR |
Profile of UroGen Pharma Ltd.
| Country | Germany |
| State | NJ |
| City | Princeton |
| Address | 400 Alexander Park |
| ZIP | 08540 |
| Phone | 646 768 9780 |
| Website | https://www.urogen.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 194 |
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Q&A For UroGen Pharma Ltd. Stock
What is a current UR8.F stock price?
UroGen Pharma Ltd. UR8.F stock price today per share is 15.5 EUR.
How to purchase UroGen Pharma Ltd. stock?
You can buy UR8.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for UroGen Pharma Ltd.?
The stock symbol or ticker of UroGen Pharma Ltd. is UR8.F.
Which industry does the UroGen Pharma Ltd. company belong to?
The UroGen Pharma Ltd. industry is Biotechnology.
How many shares does UroGen Pharma Ltd. have in circulation?
The max supply of UroGen Pharma Ltd. shares is 39.63M.
What is UroGen Pharma Ltd. Price to Earnings Ratio (PE Ratio)?
UroGen Pharma Ltd. PE Ratio is now.
What was UroGen Pharma Ltd. earnings per share over the trailing 12 months (TTM)?
UroGen Pharma Ltd. EPS is -3 EUR over the trailing 12 months.
Which sector does the UroGen Pharma Ltd. company belong to?
The UroGen Pharma Ltd. sector is Healthcare.